Call for proposals for feasibility studies now open
APPLICATION DEADLINE: 27 JULY 2020
Members* of the Vax-Hub Users Group are invited to submit proposals for funding to support feasibility studies. Funding of between £75,000 and £100,000 (including VAT, where applicable) per project is available.
Projects are expected to focus on research and development studies that lie within preparedness, technology readiness, rapid response activity or that draw on existing insights to test and validate solutions. Projects could draw on or develop current research, for example, that which was funded by the previously advertised Vax-Hub Interaction Voucher scheme or lay the foundations for more substantive future research. All projects should have outcomes that primarily benefit LMI countries. Users are expected to provide industry supervision to the project and provide access to the necessary materials, equipment or data.
Proposals may choose to focus on one or more of the following areas:
- VLP vaccines
- Formulation, thermostability
- Glycoconjugated vaccines
- Viral vectored vaccines
- Health economics
- Decisional tools (cost of goods, supply chain management, etc.)
Feasibility studies funding is awarded competitively. Applications will be via a one-stage process that will include the submission of an application form, work plan and costings. Proposals, including the budget application, should be developed by the user organisation(s) in collaboration with the academic partner/Hub researcher(s) if involved in the project.
To apply, please see further details in this document
and complete the following
(for the other formats please email firstname.lastname@example.org)
*Applications will be accepted from organisations that are in the process of joining the Hub and awards will be made subject to the completion of the required documentation by 27 July 2020.
Vax-Hub is pleased to announce the award of interaction vouchers to support the following collaborative activity.
|Hilleman Labs & UCL||Establishing the use of microscale chromatography-for downstream process optimization of Group B streptococcus polysaccharides|
|Phenotypeca Ltd and the University of Oxford||Exploiting the genetic diversity of Saccharomyces cerevisiae for VLP production|
|Sartorius Stedim Biotech and the University of Oxford||Cost of goods evaluation of adenovirus-based vaccine against Coronavirus|
|Sartorius Stedim Biotech and the University of Oxford||Improving scalability and productivity of an adenovirus-based vaccine against Coronavirus|
|Univercells, University of Leeds & UCL||Proof of principle synthesis of polio virus-like particles in an E. coli cell-free manufacturing platform|
|Vironova and UCL||MiniTEM analysis: characterisation of Viral Vaccines, Vectors and VLPs|
Platform funding will be awarded to members* of the Vax-Hub Users Group only. If you are not currently a member of the Hub but would be interested in joining to access this and other Hub benefits, please contact Jane Doogan, Vax-Hub Project Manager: email@example.com